Melasma: Pathophysiology and Why It Resists Treatment

Melasma is one of the most commonly seen pigmentary conditions in aesthetic practice, and also one of the most frustrating to manage. Unlike a simple sunspot, it rarely resolves with a single intervention, and even well-executed treatment plans are prone to relapse. Understanding why requires looking past the visible brown patches to the vascular and hormonal biology operating underneath the skin.

Not Just "Too Much Melanin"

Melasma presents as symmetrical, blotchy hyperpigmentation, typically across the cheeks, forehead, upper lip or chin, and it is tempting to treat it as a straightforward case of excess melanin production. The reality is more layered. Histological studies consistently show that affected skin has an increased number of blood vessels and altered dermal structure alongside the pigment change, which is why melasma is now generally understood as a disorder involving the melanocyte, the surrounding keratinocytes, the dermal vasculature and the basement membrane together, not an isolated pigment-cell problem.

The Vascular Component

Increased dermal vascularity is a defining feature in many melasma lesions, and vascular endothelial growth factor (VEGF) released by sun-exposed keratinocytes appears to stimulate both new blood vessel formation and melanocyte activity in the same tissue. This vascular link helps explain two clinically observed patterns: lesions often appear slightly erythematous before browning becomes obvious, and purely pigment-targeted treatments that ignore the vascular component tend to produce incomplete or short-lived results.

Hormonal and UV Triggers

Melasma has well-documented associations with:

• UV and visible light exposure, which activates melanocytes directly and drives the keratinocyte signalling described above.
• Hormonal influences, including pregnancy, oral contraceptives and hormone therapy, which is why the condition is more frequently reported in women and sometimes referred to by the lay term "mask of pregnancy."
• Genetic predisposition and skin phototype, with higher reported prevalence in darker Fitzpatrick categories.

Because these triggers can act in combination and over long timescales, a lesion that is clinically "cleared" has not had its underlying predisposition removed. A single UV exposure, a hormonal shift or heat exposure can reactivate pigment production in previously treated skin.

Why the Basement Membrane Matters

Melasma is also associated with a disrupted dermal-epidermal basement membrane, which allows pigment-containing cells and melanin to migrate into the upper dermis in some cases. This is the biological basis for classifying melasma as epidermal, dermal or mixed depth on clinical and sometimes Wood's lamp assessment, a distinction that matters because deeper, dermal-component pigment responds far more slowly, and more incompletely, to treatments that primarily act on the epidermis.

Why Relapse Is the Rule, Not the Exception

Taken together, these mechanisms explain the clinical reputation melasma has for relapsing:

| Driver | Why it undermines durable clearance | |---|---| | Ongoing vascular component | Pigment-focused treatment alone may leave the vascular driver active | | Repeat UV/visible light exposure | Reactivates melanocytes even after apparent clearance | | Hormonal fluctuation | Can retrigger pigmentation independent of prior treatment | | Dermal pigment component | Slower to respond, more likely to persist under epidermal-only approaches | | Inflammation from aggressive treatment | Paradoxically can worsen pigmentation (post-inflammatory hyperpigmentation) |

This is also why aggressive, high-intensity interventions are approached cautiously by clinicians: a treatment that provokes inflammation can trigger post-inflammatory hyperpigmentation that compounds the original problem, particularly in higher Fitzpatrick skin types.

The Takeaway

Melasma's resistance to lasting clearance is not a sign that available tools are inadequate; it reflects a genuinely multifactorial condition with vascular, hormonal, genetic and structural drivers that persist after visible pigment fades. For clinicians, this reinforces the case for strict, continuous photoprotection as a foundation alongside any active treatment, and for distributors and procurement teams, it underscores why product categories addressing pigmentation are evaluated on mechanism and evidence rather than marketed as a one-time fix.

This article is educational and does not constitute medical advice. Product selection, dosing and administration must always be performed by a qualified healthcare professional.